Kowa Co Ltd is a Japan-based company engaged in manufacture and sale of welfare equipment. The company is involved in the production and sales of welfare nursing care products including walking cars and walking aids or walk assistance carts, silver cars, handrails, walking canes, bath related products, toilet-related products and life-support products. It supplies its products mainly to chain stores, wholesale trading companies for welfare equipment, national welfare equipment lease companies, department stores, mail-order companies and others.
相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
招募中
1
100.0%
暂无批准数据
- China's National Medical Products Administration accepted for review the NCX 470 New Drug Application submitted in August 2026 by licensee Ocumension Therapeutics. - NCX 470 is a nitric oxide-donating bimatoprost eye drop that lowers intraocular pressure through two distinct pathways in open-angle glaucoma or ocular hypertension. - The Chinese review is expected to take 12 to 18 months, with a decision anticipated after the U.S. FDA's 30 April 2027 PDUFA date. - Ocumension has paid Nicox EUR 18 million in license fees, funded 50% of the Denali trial, and will pay tiered royalties of 6% to 12% on sales.
- Nicox has successfully completed generation and analysis of all clinical trial and long-term stability data required for New Drug Applications (NDAs) in the U.S. and China for NCX 470, a novel nitric oxide-donating bimatoprost eye drop for glaucoma treatment. - The company is preparing for a pre-NDA meeting with the FDA and remains on track to submit the U.S. NDA in the first half of 2026, with China submission expected shortly after. - NCX 470 represents a potential advancement in glaucoma therapy as a nitric oxide-donating formulation designed to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
